Read nextGenentech, Roche complete enrollment in phase 3 faricimab trials for wet AMD
Click Here to Manage Email Alerts
Patient enrollment has been completed intwo phase 3 trials of faricimabfor wet age-related macular degeneration, according to communication from Genentech.
The TENAYA and LUCERNE trials, as well as thephase 3 YOSEMITE and RHINE trials, which are studying the drug in patients with diabetic macular edema, are now fully recruited with more than 3,000 patients.
Faricimab, a bispecific antibody that simultaneously binds to and neutralizes Angiopoietin-2 and VEGF-A, is being compared against Eylea (aflibercept, Regeneron) in the TENAYA and LUCERNE trials.
“Genentech remains committed to researching and developing new treatments for people living with wet AMD and other vision-threatening diseases,”Christopher Brittain,MBBS, BSc, MBA, MRCOphth,vice president and global head of Genentech’s Ophthalmology Clinical Development program, said in the release. “The impact of wet AMD and DME on patients, their families and caregivers is one of the reasons Genentech and Roche are dedicated to bringing novel treatments to patients. We are so thankful to these patients and investigators for participating in these trials, and we are proud to have fully recruited the faricimab phase 3 program well ahead of schedule.”